Global Age Related Macular Degeneration Drug Market is expected to grow at a CAGR of 5.5% during the forecast period, to reach USD 3.2 billion by 2030. The market is driven by factors such as increasing prevalence of age-related macular degeneration (AMD) and growing awareness about the disease among people.
The global age related macular degeneration drug market is segmented on the basis of type, application and region. On the basis of type, it is segmented into Lucentis, Eylea and Avastin; on the basis of application it is segmented into hospitals and clinics; on the basis of region it is segmented into North America, Latin America, Europe, Asia Pacific and Middle East & Africa regions.
- Aging population.
- Increasing prevalence of AMD.
- Increasing awareness about the disease and its treatment options.
- Availability of new drugs for the treatment of AMD.
- Growing number of clinical trials.
Industry Growth Insights published a new data on “Age Related Macular Degeneration Drug Market”. The research report is titled “Age Related Macular Degeneration Drug Market research by Types (Lucentis, Eylea, Avastin, Other), By Applications (Hospitals, Clinics, Other), By Players/Companies Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Age Related Macular Degeneration Drug Market Research Report
By Type
Lucentis, Eylea, Avastin, Other
By Application
Hospitals, Clinics, Other
By Companies
Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Age Related Macular Degeneration Drug Market Report Segments:
The global Age Related Macular Degeneration Drug market is segmented on the basis of:
Types
Lucentis, Eylea, Avastin, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Regeneron Pharmaceuticals
- Bayer HealthCare
- Novartis
- Roche
- Kanghong Pharma
Highlights of The Age Related Macular Degeneration Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lucentis
- Eylea
- Avastin
- Other
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Age Related Macular Degeneration Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly. The disease causes damage to the central part of your eye, called the macula. This can lead to gradual loss of vision and eventually complete blindness. There are many different types of AMD, but all involve some degree of damage to the retina, which is at the back of your eye. Some forms may only affect one side or corner of your eyes, while others may progress more slowly and cause partial or total blindness over time.nnThere is no cure for AMD, but there are treatments that can help improve symptoms and delay or prevent vision loss. Some common treatments include laser surgery to remove damaged tissue from your eyes; medication such as rivastigmine (Exelon); and wearing special glasses or contact lenses that help block harmful light rays from reaching your eyes
Some of the major players in the age related macular degeneration drug market are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma.
The age related macular degeneration drug market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Age Related Macular Degeneration Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Age Related Macular Degeneration Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Age Related Macular Degeneration Drug Market - Supply Chain
4.5. Global Age Related Macular Degeneration Drug Market Forecast
4.5.1. Age Related Macular Degeneration Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Age Related Macular Degeneration Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Age Related Macular Degeneration Drug Market Absolute $ Opportunity
5. Global Age Related Macular Degeneration Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Age Related Macular Degeneration Drug Market Size and Volume Forecast by Type
5.3.1. Lucentis
5.3.2. Eylea
5.3.3. Avastin
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Age Related Macular Degeneration Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Age Related Macular Degeneration Drug Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Age Related Macular Degeneration Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Age Related Macular Degeneration Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Age Related Macular Degeneration Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Age Related Macular Degeneration Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Age Related Macular Degeneration Drug Demand Share Forecast, 2019-2026
9. North America Age Related Macular Degeneration Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Age Related Macular Degeneration Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Age Related Macular Degeneration Drug Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Age Related Macular Degeneration Drug Market Size and Volume Forecast by Type
9.7.1. Lucentis
9.7.2. Eylea
9.7.3. Avastin
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Age Related Macular Degeneration Drug Demand Share Forecast, 2019-2026
10. Latin America Age Related Macular Degeneration Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Age Related Macular Degeneration Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Age Related Macular Degeneration Drug Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Age Related Macular Degeneration Drug Market Size and Volume Forecast by Type
10.7.1. Lucentis
10.7.2. Eylea
10.7.3. Avastin
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Age Related Macular Degeneration Drug Demand Share Forecast, 2019-2026
11. Europe Age Related Macular Degeneration Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Age Related Macular Degeneration Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Age Related Macular Degeneration Drug Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Age Related Macular Degeneration Drug Market Size and Volume Forecast by Type
11.7.1. Lucentis
11.7.2.Eylea
11.7.3. Avastin
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Age Related Macular Degeneration Drug Demand Share, 2019-2026
12. Asia Pacific Age Related Macular Degeneration Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Age Related Macular Degeneration Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Age Related Macular Degeneration Drug Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Age Related Macular Degeneration Drug Market Size and Volume Forecast by Type
12.7.1. Lucentis
12.7.2. Eylea
12.7.3. Avastin
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Age Related Macular Degeneration Drug Demand Share, 2019-2026
13. Middle East & Africa Age Related Macular Degeneration Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Age Related Macular Degeneration Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Age Related Macular Degeneration Drug Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Age Related Macular Degeneration Drug Market Size and Volume Forecast by Type
13.7.1. Lucentis
13.7.2. Eylea
13.7.3. Avastin
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Age Related Macular Degeneration Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Age Related Macular Degeneration Drug Market: Market Share Analysis
14.2. Age Related Macular Degeneration Drug Distributors and Customers
14.3. Age Related Macular Degeneration Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Regeneron Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer HealthCare
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Kanghong Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
